Andrew R. Allen
Board Member
Adaptimmune Therapeutics PLC (ADAPY)Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Andrew R. Allen
Andrew R. Allen is recorded as Board Member at Adaptimmune Therapeutics PLC (ADAPY). Adaptimmune Therapeutics PLC reported in an 8-K filed June 1, 2023 that Andrew R. Allen was appointed director, effective June 1, 2023.
“the Adaptimmune Board appointed Andrew R. Allen, M.D., Ph.D.; Priti Hegde, Ph.D.; and Garry E. Menzel, Ph.D., each of whom were members of the board of directors of TCR^2^, to serve as directors for a term commencing upon the Effective Time.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Current
2023-06-01–present
Company network
Recorded roles and call appearances connecting this person to public companies.
Leadership on record at Adaptimmune Therapeutics PLC
Other people whose current roles at this company are on record from its filings.
- Adrian Rawcliffe CEO, Board Member
- David M. Mott Chairman
- Christopher Hill CFO
- William Bertrand COO
- Ali Behbahani Board Member
- Andrew Allen Board Member
- Andrew Allen, MD, PhD Board Member
- Dr Priti Hegde Board Member
- Garry E. Menzel Board Member
- Garry Menzel Board Member
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.